Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs
Goldman Sachs analyst Richard Law lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $15 from $29 and keeps a Neutral rating ...